RESEARCH PAPER
Elimination kinetics of synthetic interferon inducer tilorone in experimental animals
 
More details
Hide details
1
Opole Medical School, Opole, Poland
2
Department of Biology, Odessa National University, Odessa, Ukraine
3
Department of Biotechnology and Molecular Biology, University of Opole, Poland
CORRESPONDING AUTHOR
Maksym Żuk   

Opole Medical School, Opole, Poland, W. Sikorskiego, 7, 45-051 Opole, Poland
 
J Pre Clin Clin Res. 2017;11(2):127–131
KEYWORDS
TOPICS
ABSTRACT
Introduction:
A comparative investigation was carried out on the kinetics of [3H]-tilorone ([3H]-I) excretion in rats and mice.

Material and methods:
Kinetics of urinary and biliary excretion of [3H]-I in rats and mice was studied following a single oral and intravenous administration. The excretion mass balance was monitored in the faeces and urine of rats and mice for 5 and 10 days, respectively. Radioactivity was determined in the samples of excreta using a liquid scintillation counter.

Results:
In rats, [3H]-I were nearly fully (~80%) eliminated with excreta in 5 days, indicating a lack of any significant accumulation of the drug in the body. Faecal excretion of tilorone predominated (69.0% ± 2.8%), while the elimination in urine was less significant (9.8%8 ± 1.2%). A different pattern of elimination kinetics was observed in mice as excretion proceeded with equal efficiency in urine (27.85–28.9%) and faeces (26.45– 24.4 %), regardless of the route of administration of the substance and at a substantially slower rate compared to rats: only 57.35–52.68% of total radioactivity was eliminated over 10 days following oral and intravenous administration of tilorone, respectively. MRT of tilorone in rats was 36 h and in mice 120–150 h.

Conclusions:
Parameters for the excretion of tilorone showed significant differences between the 2 groups of animals. Using the example of tilorone excretion kinetics validates the presented novel modified approach to determine the mean residence time (MRT) and amount of drug eliminated from the body during an infinitely long experimental period. This approach can be generally applied for interpretation of nonlinear elimination kinetics of xenobiotics.

 
REFERENCES (19)
1.
Chandra P, Wright GJ. Tilorone hydrochloride: the drug profile. Top Curr Chem. 1977; 72: 125-126.
 
2.
Ershov FI. Amixin application in the therapy of acute and chronic viral infections. Moscow: Medi-cine; 1998.
 
3.
Hiyama Y, Kuriyama K. Dissociation between antiinflammatory action of tilorone and its interfer-on inducing activity. Agents Actions, 1991; 33: 229-232.
 
4.
Koval’chuk AV, Borisevich SV, Syromiatnikova SI, et al. Antiviral activity of an interferon induc-er amixin in experimental West Nile Fever. Vopr Virusol. 2004; 49(2): 8-11, Russian.
 
5.
Kremerman IB, Prijmiagi LS, Ershov FI. Experimental study of the interferonogenic and antiviral activity of biologically active substances.Vopr Virusol. 1984; 29(5): 549-553, Russian.
 
6.
Liakhov SA, Litvinova LA, Andronati SA et al. Biochemical mechanisms of realization of antiviral and interferon-inducing activity of amixine and its analogs. Ukr Biokhim Zh. 2001; 73(4): 108-113, Russian.
 
7.
Basley WA, Rees RC, Greager JA, Baldwin RW. Antitumour effects of tilorone hydrochloride on the in vivo growth of chemically induced and spontaneously arising rat tumours. Chemotherapy, 1981; 27: 44-47.
 
8.
Zhou D, Tuo W, Hu H, el al. Synthesis and activity evaluation of tilorone analogs as potential anti-cancer agents. Eur J Med Chem. 2013; 64: 432-441.
 
9.
Skrots'ka OI, Zholobak NM, Antonenko SV, Spivak MIa, Karpov OV. Antiherpetic effect of RNA-tilorone molecular complex in cell culture. Mikrobiol Z. 2007; 69(3): 62-68. Ukrainian.
 
10.
Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A. Alpha/beta interferon differen-tially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear fac-tor 1alpha-null HBV transgenic mice. J Virol. 2005; 79(17): 11045-11052.
 
11.
Semenenko TA, Selkova EP, Nikitina GY et al. Immunomodulators in the prevention of acute res-piratory viral infections. Russian Journal Immunology 2002; 7: 105-114.
 
12.
Sokolova TM, Uryvaev LV, Tazulakhova EB, Ershov FI, Malyshenkova IK, Didkovskiĭ NA. Indi-vidual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon. Vopr Virusol. 2005; 50(2): 32-36, Russian.
 
13.
Gaur V, Chandra P. Subcellular distribution of 14C-tilorine hydrochloride in tissues of mice and rats. Naturwissenschaften, 1973; 60: 263.
 
14.
Zhuk OV, Maltsev GV, Sumriy SK. The synthesis and pharmacokinetics of 3H-amixin, a low molecular weight synthetic interferon inductor, in experimental animals. Drug of the Future, 2002; 27(Supp l): 549.
 
15.
Zinkovsky VG, Zhuk OV, Sumriy SK. Pharmacokinetic of a synthetic interferon inducer amixin in mice. Pharmacol Rep. 2007; 59. 739-751.
 
16.
Golovenko NY, Borisyuk IY. Pharmacokinetics of amixin after repeated peroral administration to mice. Bull Exp Biol Med. 2005; 140(6): 708-710.
 
17.
Zinkovsky VG, Zhuk OV. Estimation of the characteristic residence time and excretion parameters of xenobiotic in cocase of the its multicompartment distribution. Proceeding of the 14-th National Conference on Applications of Mathematics in Biology and Medicine, 2008; 140-145.
 
18.
Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: An add-in program for pharmacokinetic and pharmacodynamics data analysis in Microsoft Excel. Comput Methods Programs Biomed. 99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007.
 
19.
Karpinchik VA, Maltsev GV, Sumriy SK. Synthesis of amixin- 3H2 and methods to extract amixin from biological material. Khim Farm Zh. 2002; 8: 47-49. Russian.
 
eISSN:1898-7516
ISSN:1898-2395